peoplePerson
Bob T. Li
Ran the trials that made trastuzumab deruxtecan the first HER2-directed drug for lung cancer.
Thoracic oncologist who led DESTINY-Lung01, establishing T-DXd in HER2-mutant NSCLC, and early studies of HER2-directed therapy in lung cancer. Also leads MSK's Asia-Pacific partnerships.
Role
Physician Ambassador to China and Asia-Pacific; Medical Oncologist, Thoracic Oncology
Institution
Specialisms
HER2-mutant lung cancerAntibody-drug conjugatesEarly drug development
Profiles
| Title | Journal | Year |
|---|---|---|
| Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer | New England Journal of Medicine | 2022 |
Pages like this
not linked directly; found by shared links- ProductTrastuzumab duocarmazine
Shares Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC).
- TrialDESTINY-CRC02
Shares Trastuzumab deruxtecan, HER2.
- TrialSOHO-01
Shares HER2, Non-small-cell lung cancer.
- TrialDESTINY-PanTumor02
Shares Trastuzumab deruxtecan, HER2, Antibody-drug conjugate (ADC).
- IdeaContinuous-flow synthesis of ultra-potent ADC payloads to ease the capacity squeeze
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- ProductSevabertinib
Shares Trastuzumab deruxtecan, HER2, Non-small-cell lung cancer.
- PersonNoboru Yamamoto
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).
- PersonToshihiko Doi
Shares Trastuzumab deruxtecan, Antibody-drug conjugate (ADC).